Drugs / Duvortuxizumab
Duvortuxizumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02743546 | Jul 2016 → Sep 2018 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT02454270 | Jun 2015 → Jul 2018 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duvortuxizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743546 ↗ |
| Known as | hBU12(2.4)-hXR32-MP3 M1.2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990037 ↗ |
| Known as | JNJ-64052781 | “Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma” NCT02743546 ↗ |
| Known as | MGD011 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990037 ↗ |
| Known as | RES192M1.2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990037 ↗ |
| Modality | Protein / enzyme biologic | “CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein” NCT02454270 ↗ |
| Route | Intravenous | “administered intravenously” NCT02454270 ↗ |